Literature DB >> 29143277

Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma.

Hiroaki Nagashima1, Takashi Sasayama2, Kazuhiro Tanaka1, Katsusuke Kyotani3, Naoko Sato1, Masahiro Maeyama1, Masaaki Kohta1, Junichi Sakata1, Yusuke Yamamoto1, Kohkichi Hosoda1, Tomoo Itoh4, Ryohei Sasaki5, Eiji Kohmura1.   

Abstract

It is sometimes difficult to distinguish gliomas from other tumors on routine imaging. In this study, we assessed whether 3-T magnetic resonance spectroscopy (MRS) with LCModel software might be useful for discriminating glioma from other brain tumors, such as primary central nervous system lymphomas (PCNSLs) and metastatic tumors. A total of 104 cases of brain tumor (66 gliomas, 20 PCNSLs, 6 metastatic tumors, 12 other tumors) were preoperatively investigated with short echo time (35 ms) single-voxel 3-T MRS. LCModel software was used to evaluate differences in the absolute concentrations of choline, N-acetylaspartate, N-acetylaspartylglutamate, glutamate + glutamine, myo-inositol (mIns), and lipid. mIns levels were significantly increased in high-grade glioma (HGG) compared with PCNSL (p < 0.001). In multivariate logistic regression analysis, mIns was the best marker for differentiating HGG from PCNSL (p < 0.0001, odds ratio 1.9927, 95% confidence interval 1.3628-3.2637). Conventional MRS detection of mIns resulted in a high diagnostic accuracy (sensitivity, 64%; specificity, 90%; area under the receiver operator curve, 0.80) for HGG. The expression of inositol 3-phosphate synthase (ISYNA1) was significantly higher in gliomas than in PCNSLs (p < 0.05), suggesting that the increased level of mIns in glioma is due to high expression of ISYNA1, the rate-limiting enzyme in the mIns-producing pathway. In conclusion, noninvasive analysis of mIns using single-voxel MRS may be useful in distinguishing gliomas from other brain tumors, particularly PCNSLs.

Entities:  

Keywords:  Glioma; MR spectroscopy; Metabolomics; Myo-inositol; Primary central nervous system lymphoma

Mesh:

Substances:

Year:  2017        PMID: 29143277     DOI: 10.1007/s11060-017-2655-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Automatic quantitation of localized in vivo 1H spectra with LCModel.

Authors:  S W Provencher
Journal:  NMR Biomed       Date:  2001-06       Impact factor: 4.044

2.  Early prediction of response to Vorinostat in an orthotopic rat glioma model.

Authors:  Li Wei; Samuel Hong; Younghyoun Yoon; Scott N Hwang; Jaekeun C Park; Zhaobin Zhang; Jeffrey J Olson; Xiaoping P Hu; Hyunsuk Shim
Journal:  NMR Biomed       Date:  2012-02-02       Impact factor: 4.044

3.  Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  R Stupp
Journal:  Ann Oncol       Date:  2007-04       Impact factor: 32.976

4.  (1)H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery.

Authors:  Paloma Mora; Carles Majós; Sara Castañer; Juan J Sánchez; Andreu Gabarrós; Amadeo Muntané; Carles Aguilera; Carles Arús
Journal:  Eur Radiol       Date:  2014-07-17       Impact factor: 5.315

5.  Measurement of biosynthesis of myo-inositol from glucose 6-phosphate.

Authors:  F Eisenberg; R Parthasarathy
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  Molecular MRI differentiation between primary central nervous system lymphomas and high-grade gliomas using endogenous protein-based amide proton transfer MR imaging at 3 Tesla.

Authors:  Shanshan Jiang; Hao Yu; Xianlong Wang; Shilong Lu; Yufa Li; Lyujin Feng; Yi Zhang; Hye-Young Heo; Dong-Hoon Lee; Jinyuan Zhou; Zhibo Wen
Journal:  Eur Radiol       Date:  2015-04-30       Impact factor: 5.315

7.  Linear discriminant analysis of brain tumour (1)H MR spectra: a comparison of classification using whole spectra versus metabolite quantification.

Authors:  K S Opstad; C Ladroue; B A Bell; J R Griffiths; F A Howe
Journal:  NMR Biomed       Date:  2007-12       Impact factor: 4.044

8.  Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.

Authors:  Koji Yamashita; Akio Hiwatashi; Osamu Togao; Kazufumi Kikuchi; Yoshiyuki Kitamura; Masahiro Mizoguchi; Koji Yoshimoto; Daisuke Kuga; Satoshi O Suzuki; Shingo Baba; Takuro Isoda; Toru Iwaki; Koji Iihara; Hiroshi Honda
Journal:  J Magn Reson Imaging       Date:  2016-04-19       Impact factor: 4.813

9.  Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey.

Authors:  Ingfrid S Haldorsen; Bård K Krossnes; Jan H Aarseth; David Scheie; Tom B Johannesen; Olav Mella; Ansgar Espeland
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

10.  Myo-inositol: a marker of reactive astrogliosis in glial tumors?

Authors:  Elke Hattingen; Peter Raab; Kea Franz; Friedhelm E Zanella; Heinrich Lanfermann; Ulrich Pilatus
Journal:  NMR Biomed       Date:  2008-03       Impact factor: 4.044

View more
  9 in total

Review 1.  Clinical Applications of Magnetic Resonance Spectroscopy in Brain Tumors: From Diagnosis to Treatment.

Authors:  Brent D Weinberg; Manohar Kuruva; Hyunsuk Shim; Mark E Mullins
Journal:  Radiol Clin North Am       Date:  2021-03-23       Impact factor: 2.303

2.  Hydrogen Proton Magnetic Resonance Spectroscopy (MRS) in Differential Diagnosis of Intracranial Tumors: A Systematic Review.

Authors:  Lin Wang; Guanfeng Chen; Kaifeng Dai
Journal:  Contrast Media Mol Imaging       Date:  2022-05-18       Impact factor: 3.009

3.  The Association Between Breast Cancer and Blood-Based Methylation of CD160, ISYNA1 and RAD51B in the Chinese Population.

Authors:  Chunlan Liu; Xiajie Zhou; Jialie Jin; Qiang Zhu; Lixi Li; Qiming Yin; Tian Xu; Wanjian Gu; Fei Ma; Rongxi Yang
Journal:  Front Genet       Date:  2022-06-09       Impact factor: 4.772

4.  Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma.

Authors:  Masahiro Maeyama; Takashi Sasayama; Kazuhiro Tanaka; Satoshi Nakamizo; Hirotomo Tanaka; Masamitsu Nishihara; Yuichi Fujita; Kenji Sekiguchi; Masaaki Kohta; Katsu Mizukawa; Takanori Hirose; Tomoo Itoh; Eiji Kohmura
Journal:  Cancer Med       Date:  2020-04-20       Impact factor: 4.452

5.  Bilingualism is a long-term cognitively challenging experience that modulates metabolite concentrations in the healthy brain.

Authors:  Christos Pliatsikas; S M Pereira Soares; T Voits; V Deluca; J Rothman
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

6.  Evidence of persistent glial cell dysfunction in the anterior cingulate cortex of juvenile idiopathic arthritis children: a proton MRS study.

Authors:  Haiwei Han; Ji Hong Xiao; Yifei Weng; Hongyan Liang; Chengkun Han; Cuili Yi; Kezhao Lin; Hua Wu
Journal:  Pediatr Rheumatol Online J       Date:  2022-07-27       Impact factor: 3.413

7.  A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy.

Authors:  Xin Shen; Natalie L Voets; Sarah J Larkin; Nick de Pennington; Puneet Plaha; Richard Stacey; James S O McCullagh; Christopher J Schofield; Stuart Clare; Peter Jezzard; Tom Cadoux-Hudson; Olaf Ansorge; Uzay E Emir
Journal:  Metabolites       Date:  2019-02-20

Review 8.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

9.  Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1-p21/ZEB-1 pathway.

Authors:  Lei Zhou; WeiWei Sheng; Chao Jia; Xiaoyang Shi; Rongxian Cao; Guosen Wang; Yiheng Lin; Fang Zhu; Qi Dong; Ming Dong
Journal:  J Cell Mol Med       Date:  2020-08-11       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.